Anti-diabetic drugs treat diabetes by lowering glucose levels in the blood. One class of anti-diabetic drugs that are used in the management of diabetes is Sulfonylurea. Sulfonylurea derivatives are used in the management of diabetes mellitus type 2. They act by increasing insulin release from the beta cells in the pancreas. Diabetes mellitus type 2[…]
Sulfonylurea Class Antidiabetic Drugs
Anti-Diabetic, Bulk Active Ingredient, Compounding API, OTC and Compounding Product Tags: anemiaanti-diabetictype 2 Diabetes Nov 23, 2010
LGM Pharma Supplies Ingredients for Several Anti-Obesity Drugs
Anti-Migraine, Anti-Obesity Product, Bulk Active Ingredient, Compounding API, Drug Research & Development API Tags: Drug AdministrationlorcaserinObesityTopiramate Aug 31, 2010
LGM Pharma supplies Topiramate, Bupropion, Naltrexone and Lorcaserin – Active Pharmaceutical Ingredients (APIs) used to treat obesity.
Nalbuphine Hydrochloride (HCL) API for Compounding Purposes
Bulk Active Ingredient, Compounding API, OTC and Compounding Product Aug 12, 2010
Nalbuphine Hydrochloride CAS# 23277-43-2 (Nalbuphine Hydrochloride) is a synthetic opioid used commercially as an analgesic under a variety of trade names, including Nubain. It is noteworthy in part for the fact that at low dosages, it is found much more effective by women than by men, and may even increase pain in men, leading[…]
TAPI (Teva Active Pharmaceutical Ingredients) TAPI is an international supplier of active pharmaceutical ingredients, with more than $1.9 Billion in annual sales. TAPI employs over 4,600 professionals worldwide and boasts a portfolio of over 290 active pharmaceutical ingredients. TAPI is a stand alone business unit within Teva Pharmaceutical Industries Limited and as its mother company[…]
Darunavir Ethanolate – Anti-Retroviral / Anti-HIV Therapeutic
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: Darunavir EthanolateHIVNorvir Jul 21, 2010
Darunavir Ethanolate CAS# 635728-49-3 is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs. Darunavir is always[…]